Tuodao Medical

Tuodao Medical has emerged as a diversified surgical robotics company with a broad portfolio spanning orthopedic, laparoscopic, percutaneous, and imaging systems. Founded in 2018 by Dr. Cheng Min, a robotics expert who was inspired after witnessing robot-assisted surgery in Germany, the Nanjing-based company has achieved rapid commercialization with eight NMPA-approved products as of 2025.

Company Overview

Tuodao Medical Technology Co., Ltd. positions itself as both a surgical robot manufacturer and intelligent medical solutions provider. The company has built a core technology platform encompassing data algorithms, artificial intelligence, and precision intelligent control systems. This foundation supports product development across five strategic segments: orthopedics, laparoscopic surgery, percutaneous intervention, natural orifice transluminal endoscopic surgery (NOTES), and intraoperative imaging equipment.

The company maintains its headquarters in Nanjing’s Yuhuatai District with additional operations including a Singapore R&D center established in 2021. With over 400 employees, Tuodao has assembled teams spanning clinical research, robotic engineering, and regulatory affairs to support its multi-platform development strategy.

Core Products

Tuoshou® Orthopedic Surgical Robot (NS100)

The flagship Tuoshou® Trinity system received NMPA approval in 2022 (Registration No. 国械注准 20223011042), establishing Tuodao’s commercial presence in the orthopedic robotics market. The system comprises a master control execution unit and optical tracking system designed for spinal, trauma, and joint surgeries. Surgeons use preoperative CT or intraoperative C-arm images to plan screw trajectories and entry points, with the robotic arm providing precise positioning according to the surgical plan. Real-time position monitoring through the optical tracking system ensures procedural safety while reducing radiation exposure for both patients and surgical teams.

Tuoshu® Percutaneous Surgical Robot (NP100)

Approved in 2023 following successful clinical trials, the Tuoshu® percutaneous system extends Tuodao’s reach into image-guided interventional procedures. The robot assists with needle placement accuracy in procedures requiring precise percutaneous access.

Tuoling® Laparoscopic Surgical Robot (YC100)

The newest addition to Tuodao’s portfolio, the Tuoling® laparoscopic system received NMPA approval in 2025 after completing registration clinical trials across urology, gynecology, and general surgery applications in 2024. This multi-arm system represents Tuodao’s entry into the competitive laparoscopic robotics market.

Imaging Systems

Complementing its robotic platforms, Tuodao offers the Daoying 3D Mobile C-arm and Tuoying® Mobile C-arm X-ray systems, both approved in 2023. These imaging solutions integrate with the company’s orthopedic robot to provide a full spinal surgery solution.

Technology & Innovation

Tuodao’s technical approach emphasizes integration between imaging, navigation, and robotic execution. The company’s “hyper-fusion” concept combines surgical robots with C-arm imaging into unified workflows, addressing the clinical need for real-time visualization during robot-assisted procedures. The optical tracking technology employed across platforms enables continuous position verification without requiring patient-attached trackers, reducing procedural complexity.

Market Presence

Tuodao has achieved commercial traction in the domestic Chinese market, with notable hospital procurement wins. In 2024, the company secured a competitive tender at Ningbo No. 2 Hospital for orthopedic surgical navigation, winning despite not offering the lowest price—a outcome attributed to superior technical evaluation scores from clinical experts assessing functionality and parameters.

The company debuted at major industry events in 2023, including the inaugural Global Conference on Surgical Robotics and the Chinese Orthopaedics Association (COA) Annual Meeting. The Tuoling laparoscopic system was subsequently showcased at the 2024 Chinese Urological Association (CUA) Annual Meeting following completion of urological clinical trials.

Key Milestones

• 2018: Company founded by Dr. Cheng Min in Nanjing
• 2020: Commenced pre-clinical trials for NS100 orthopedic robot
• 2021: Established Singapore R&D center
• 2022: NS100 Tuoshou® orthopedic robot received NMPA approval; recognized as “WISE2022 Invisible Champion”
• 2023: Three products approved—Daoying 3D C-arm, Tuoying® C-arm, and NP100 Tuoshu® percutaneous robot
• 2024: Completed multi-specialty clinical trials for YC100 Tuoling® laparoscopic robot
• 2025: Tuoling® laparoscopic surgical robot received NMPA approval

Frequently Asked Questions

What surgical robots does Tuodao Medical manufacture?

Tuodao produces three main robotic systems: the Tuoshou® orthopedic robot for spine, trauma, and joint procedures; the Tuoshu® percutaneous surgical robot for image-guided interventions; and the Tuoling® laparoscopic robot for minimally invasive abdominal and pelvic surgery. The company also manufactures complementary mobile C-arm imaging systems.

Is Tuodao Medical publicly traded?

No, Tuodao Medical is currently a private company. The company has not announced IPO plans as of 2025.

How many products has Tuodao Medical received approval for?

As of 2025, Tuodao has received NMPA approval for eight products, including three surgical robot systems and multiple imaging devices.